FENC | Fennec Pharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.95 - 6.18
52 Week Range	3.96 - 11.49
Beta	0.76
Implied Volatility	252.22%
IV Rank	96.08%
Day's Volume	57,633
Average Volume	121,162
Shares Outstanding	27,427,700
Market Cap	166,760,416
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-09-15

Valuation
Profitability
Growth
Health
P/E Ratio	-152.00
Forward P/E Ratio	N/A
EPS	-0.04
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	29
Country	USA
Website	FENC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

FENC's peers: ATXS, CUE, CYCN, MOLN, MNOV, ANEB, CSBR, CYT, KROS, JANX, EWTX, HRMY, IKNA, AVTE, ELYM, DBTX, OLMA, IRON, LRMR, OBIO, GNFT, HROW, ICCC, IMTX, INSM, MESO, PCSA, PHAR, PRTG, SVRA, TCRT, VRCA, SNTI, PMN, LIPO, COYA

*Chart delayed

Analyzing fundamentals for FENC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see FENC Fundamentals page.

Watching at FENC technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on FENC Technicals page.